Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Inclusion Criteria: * Reoccurrence or worsening of rickets for at least the past 3 months in participants who showed an initial efficacy response to asfotase alfa after at least 6 months of continuous treatment and currently receiving asfotase alfa. RSS will be used to determine severity at Baseline. * Presence of ADAs, with or without NAbs, irrespective of their titers. * Confirmation by the TMB that both the clinical evidence and immunogenicity-mediated association noted above are present. * Female participants of childbearing potential and male participants with partners of childbearing potential must follow protocol-specified contraception guidance as described in Section 10.5. * Participant, or participant's legal guardian, is capable of signing informed consent or assent as described in Section 10.1.3, which includes compliance with the requirements and restrictions listed in the informed consent or assent form and in this protocol. Exclusion Criteria: * Known history of human immunodeficiency virus (HIV) infection (evidenced by HIV type 1 or type 2 \[HIV 1, HIV 2\] antibody) or hepatitis B or C viral infection. * Known or suspected history of drug or alcohol abuse or dependence within 1 year prior to Screening. * Inability of the participant, or the participant's legal guardian, to provide informed consent. * Pregnant, breastfeeding, or intending to conceive during the course of the study. * Inability to travel to the clinic for specified visits during the Treatment…